TY - JOUR T1 - Personalised medicine in asthma: time for action JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0064-2017 VL - 26 IS - 145 SP - 170064 AU - Kian Fan Chung Y1 - 2017/09/30 UR - http://err.ersjournals.com/content/26/145/170064.abstract N2 - Asthma is a heterogeneous disease comprising several phenotypes driven by different pathways. To define these phenotypes or endotypes (phenotypes defined by mechanisms), an unbiased approach to clustering of various omics platforms will yield molecular phenotypes from which composite biomarkers can be obtained. Biomarkers can help differentiate between these phenotypes and pinpoint patients suitable for specific targeted therapies – the basis for personalised medicine. Biomarkers need to be linked to point-of-care biomarkers that may be measured readily in exhaled breath, blood or urine. The potential for using mobile healthcare approaches will help patient enpowerment, an essential tool for personalised medicine. Personalised medicine in asthma is not far off – it is already here, but we need more tools and implements to carry it out for the benefit of our patients.We need to start applying personalised medicine at all levels of severity of asthma http://ow.ly/EoXQ30e8p24 ER -